Esperance A. Schaefer

Gastroenterology | Hepatology

1153 Centre Street
Suite 4B
Jamaica Plain, MA 02130

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Development and psychometric evaluation of the Liver Disease Stigma Scale (LDSS).

Development and psychometric evaluation of the Liver Disease Stigma Scale (LDSS).

Journal: JHEP reports : innovation in hepatology

Published: February 21, 2026

Preventing cirrhosis: Why primary care clinicians should screen for liver disease in patients who drink heavily.

Preventing cirrhosis: Why primary care clinicians should screen for liver disease in patients who drink heavily.

Journal: Cleveland Clinic journal of medicine

Published: February 02, 2026

Glucagon-like peptide-1 receptor agonist reduces risk of alcohol-associated cirrhosis in type 2 diabetes and alcohol use disorder patients.

Glucagon-like peptide-1 receptor agonist reduces risk of alcohol-associated cirrhosis in type 2 diabetes and alcohol use disorder patients.

Journal: European journal of gastroenterology & hepatology

Published: November 17, 2025

Phosphatidylethanol testing: patterns, demographic and clinical correlates, and outcomes.

Phosphatidylethanol testing: patterns, demographic and clinical correlates, and outcomes.

Journal: Alcohol and alcoholism (Oxford, Oxfordshire)

Published: June 06, 2025

Integrating hepatology with addiction care for inpatients with alcohol use disorder reduces future liver-related events.

Integrating hepatology with addiction care for inpatients with alcohol use disorder reduces future liver-related events.

Journal: Hepatology communications

Published: March 16, 2025

Defining Risk in Alcohol-Associated Liver Disease Using the Model for End-Stage Liver Disease.

Defining Risk in Alcohol-Associated Liver Disease Using the Model for End-Stage Liver Disease.

Journal: The American journal of gastroenterology

Published: January 14, 2025

Evaluation of Abnormal Liver Biochemical Test Results.

Evaluation of Abnormal Liver Biochemical Test Results.

Journal: Gastroenterology

Published: December 14, 2024

Prevalence and Clinical Correlation of Cardiometabolic Risk Factors in Alcohol-Related Liver Disease and Metabolic Dysfunction and Alcohol Associated Liver Disease (MetALD).

Prevalence and Clinical Correlation of Cardiometabolic Risk Factors in Alcohol-Related Liver Disease and Metabolic Dysfunction and Alcohol Associated Liver Disease (MetALD).

Journal: Journal of clinical and experimental hepatology

Published: September 10, 2024

Reply: Is nesting addiction medicine and hepatology care in the outpatient setting worthwhile? A retrospective case series at a single tertiary center.

Reply: Is nesting addiction medicine and hepatology care in the outpatient setting worthwhile? A retrospective case series at a single tertiary center.

Journal: Hepatology communications

Published: June 20, 2024

Tofacitinib is Effective in Treating Refractory Immune Checkpoint Inhibitor Hepatitis.

Tofacitinib is Effective in Treating Refractory Immune Checkpoint Inhibitor Hepatitis.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: October 31, 2023

Case 4-2023: A 56-Year-Old Man with Abnormal Results on Liver Testing.

Case 4-2023: A 56-Year-Old Man with Abnormal Results on Liver Testing.

Journal: The New England journal of medicine

Published: February 13, 2023

Serum Fibroblast Growth Factor-21 Discriminates Between Decompensated Alcohol-Associated Cirrhosis and Severe Alcohol-Associated Hepatitis.

Serum Fibroblast Growth Factor-21 Discriminates Between Decompensated Alcohol-Associated Cirrhosis and Severe Alcohol-Associated Hepatitis.

Journal: Clinical and translational gastroenterology

Published: December 19, 2022

Showing 1-12 of 49

Last Updated: 09/26/2026